title: Anticipatory nausea in cancer patients receiving chemotherapy: classical conditioning etiology and therapeutical implications.
abstract: The delivery of cytotoxic drugs in cancer treatment is often accompanied by posttreatment side effects (e.g., nausea). Moreover, there is evidence that cancer patients are at risk to develop these side effects in anticipation of chemotherapy (i.e., anticipatory nausea [AN]). AN can be explained as the result of a classical conditioning process with the cytotoxic drug as the unconditioned stimulus (US). Stimuli paired with the US (e.g., smells, tastes) can become conditioned stimuli (CSs) eliciting AN as the conditioned response (CR). The present study was conducted to test whether AN shows characteristics of a CR. Fifty-five ambulatory cancer patients were asked to record nine kinds of physical symptoms (e.g., nausea, vomiting, sweating) on time-scheduled symptom lists: after an infusion (indicating posttreatment symptoms) and prior to their next infusion (indicating anticipatory symptoms). Each measurement period covered a maximum of 48 hours. AN was reported by ten patients (18.08%). Data revealed (a) a statistically significant association between posttreatment nausea and vomiting, respectively, and AN; (b) the occurrence of AN increased with drug emetogenity (i.e., US-intensity); and (c) the duration of AN increased with temporal proximity to the infusion. The results support the conditioning model. Thus, it is proposed to prevent AN by classical conditioning techniques (e.g., overshadowing).
authors.affiliation: Institute of Medical Psychology, Heinrich-Heine-University Duesseldorf, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Stockhorst
authors.forename: S
authors.initials: S
authors.lastname: Klosterhalfen
authors.forename: W
authors.initials: W
authors.lastname: Klosterhalfen
authors.forename: M
authors.initials: M
authors.lastname: Winkelmann
authors.forename: H J
authors.initials: HJ
authors.lastname: Steingrueber
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001245:Association Learning / Q000187:drug effects; D003214:Conditioning, Classical / Q000187:drug effects; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D007262:Infusions, Intravenous / Q000523:psychology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000523:psychology; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000523:psychology* / Q000628:therapy; D014840:Vomiting, Anticipatory / Q000523:psychology* / Q000628:therapy